Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Special report
: The Fierce 50 of 2024
multiple myeloma
Biotech
FDA rejects Regeneron bispecific, delaying rival to J&J, Pfizer
The FDA hit the Big Biotech's BCMAxCD3 bispecific antibody linvoseltamab with a complete response letter over issues at a third-party manufacturer.
Nick Paul Taylor
Aug 21, 2024 5:48am
BMS axes bispecific months after filing to run phase 3 trial
Jul 26, 2024 8:17am
AACR: Regeneron's multiple myeloma drug shows staying power
Apr 7, 2024 4:00pm
Regeneron seeks clarity on confirmatory trials after FDA hurdle
Mar 29, 2024 5:00am
Takeda drops cancer candidates amid shifting treatment landscape
Feb 2, 2024 5:33am
Regeneron's 'best-in-class' myeloma drug spurs 100% side effects
Dec 7, 2023 7:00am